Welcome to Oligasis

Oligasis is a privately held biotechnology company that is designing, manufacturing and licensing proprietary biopolymers for the pharmaceutical industry to enable the next-generation of drugs. The Company's biopolymers resolve two ubiquitous problems: for protein pharmaceuticals, extended half-life; and for small molecule pharmaceuticals, diminished toxicity.

The Company’s technology has its origins in the fundamental science of biocompatibility and is reduced to practice with native chemistries and building blocks that are familiar to today’s drug developers, manufacturers and regulators.

A Breakthrough Technology for Pharmaceuticals

We are powering a new era of disease-centric drug design.

By attaching our Extreme Biopolymers^TM to pharmaceuticals:

For stably attached drugs (e.g. biopharmaceuticals),
we shield the drug from clearance and surveillance systems, preventing rapid elimination which undermines efficacy and dosing;

For unstably attached drugs (e.g. small molecules),
we shield the drug until it arrives at its target tissue, preventing unwanted systemic toxicity and providing tailored kinetics of release.

Different drug classes (biopharmaceutical, small molecule, oligonucleotide) can be attached simultaneously with predefined stoichiometry via stable and/or unstable linkages.

:: What's New

:: Extreme Biocompatibility

:: Clinically Proven Precedent

Pfizer Collaboration

May 17, 2010. Oligasis announces pharmaceutical partnership with Pfizer in which Oligasis will apply its toolkit of Extreme Biopolymers to Pfizer's pharmaceutical programs.

Science Journal Articles

The fundamental science of water structuring drives the extreme biocompatibility of Oligasis' polymers and is the subject of recent Science articles:

Chen M et al (2009) Lubrication at Physiological Pressures by Polyzwitterionic Brushes. Science 323, 1698.

Raviv U et al (2002) Fluidity of Bound Hydration Layers. Science 297, 1540.

Marketed Medical Devices

Oligasis’ technology starts with well-established principles, proven in the following marketed medical devices, and reinvents them entirely for attachment to soluble drugs:

CooperVision's Proclear contact lenses.

Medtronic's Endeavor drug-eluting coronary stent.

Sorin's PrimO2X oxygenators and perfusion tubing systems.